AMG National Trust Bank Lowers Position in Johnson & Johnson (NYSE:JNJ)

AMG National Trust Bank reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,334 shares of the company's stock after selling 9,160 shares during the quarter. AMG National Trust Bank's holdings in Johnson & Johnson were worth $10,560,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Raymond James Financial Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth $1,339,878,000. Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 228.1% during the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after buying an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. boosted its stake in Johnson & Johnson by 11.4% in the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Holocene Advisors LP bought a new position in Johnson & Johnson in the third quarter valued at about $225,040,000. Finally, FMR LLC raised its stake in Johnson & Johnson by 7.4% during the third quarter. FMR LLC now owns 18,316,920 shares of the company's stock worth $2,968,440,000 after acquiring an additional 1,265,748 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.6 %

Shares of NYSE JNJ traded up $0.98 during midday trading on Friday, reaching $166.81. The stock had a trading volume of 9,636,645 shares, compared to its average volume of 7,032,060. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company's 50 day moving average price is $152.95 and its 200 day moving average price is $156.28. The firm has a market cap of $401.61 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson's payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on JNJ shares. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Morgan Stanley dropped their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.